QNCX Insider Trading

Insider Ownership Percentage: 16.80%
Insider Buying (Last 12 Months): $648,111.20
Insider Selling (Last 12 Months): $0.00

Quince Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Quince Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Quince Therapeutics Share Price & Price History

Current Price: $0.71
Price Change: +0.30 (1.20%)
As of 06/17/2024 12:48 PM ET

This chart shows the closing price history over time for QNCX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Quince Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2023David LamondDirectorBuy22,627$1.04$23,532.082,347,545View SEC Filing Icon  
12/12/2023David LamondDirectorBuy22,327$1.02$22,773.542,302,291View SEC Filing Icon  
12/7/2023David LamondDirectorBuy19,123$1.01$19,314.232,279,664View SEC Filing Icon  
12/5/2023David LamondDirectorBuy19,123$1.01$19,314.232,241,418View SEC Filing Icon  
12/1/2023David LamondDirectorBuy14,378$0.94$13,515.322,222,295View SEC Filing Icon  
11/29/2023David LamondDirectorBuy14,378$0.98$14,090.442,193,539View SEC Filing Icon  
8/30/2023David LamondDirectorBuy41,026$1.31$53,744.062,138,135View SEC Filing Icon  
8/17/2023David LamondDirectorBuy24,766$1.29$31,948.142,097,109View SEC Filing Icon  
8/15/2023David LamondDirectorBuy107,886$1.32$142,409.521,954,995View SEC Filing Icon  
8/10/2023Dirk ThyeCEOBuy88,000$1.26$110,880.00448,911View SEC Filing Icon  
8/8/2023Brendan HannahInsiderBuy71,762$1.22$87,549.64201,555View SEC Filing Icon  
8/8/2023Dirk ThyeCEOBuy80,000$1.24$99,200.00360,911View SEC Filing Icon  
8/8/2023Margaret McloughlinDirectorBuy8,000$1.23$9,840.008,000View SEC Filing Icon  
3/6/2023Ted MonohonCAOSell1,871$0.98$1,833.5827,440View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Quince Therapeutics (NASDAQ:QNCX)

30.75% of Quince Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at QNCX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Quince Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
1/12/2024Scharf Investments LLC91,061$96K0.0%N/A0.212%Search for SEC Filing on Google Icon
7/31/2023Intellectus Partners LLC53,527$81K0.0%N/A0.148%Search for SEC Filing on Google Icon
7/24/2023BML Capital Management LLC1,411,839$2.13M1.9%N/A3.892%Search for SEC Filing on Google Icon
5/11/2023EPIQ Capital Group LLC958,469$1.50M0.8%-9.3%2.642%Search for SEC Filing on Google Icon
4/20/2023Hennion & Walsh Asset Management Inc.31,061$48K0.0%N/A0.086%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Quince Therapeutics logo
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More on Quince Therapeutics

Today's Range

Now: $0.71
Low: $0.70
High: $0.72

50 Day Range

MA: $0.92
Low: $0.70
High: $1.11

52 Week Range

Now: $0.71
Low: $0.65
High: $1.70


12,058 shs

Average Volume

89,987 shs

Market Capitalization

$30.69 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Quince Therapeutics?

Quince Therapeutics' top insider shareholders include:
  1. David Lamond (Director)
  2. Dirk Thye (CEO)
  3. Brendan Hannah (Insider)
  4. Ted Monohon (CAO)
  5. Margaret Mcloughlin (Director)
Learn More about top insider investors at Quince Therapeutics.